DCPrime

DCPrime is a company that develops clinical stage, novel cancer immunotherapies that are based on their DCOne platform. The company was founded by Ada Kruisbeek in 2006, in Leiden, Zuid-Holland, The Netherlands.

The company's vaccines are designed for the purpose of relapse, and are designed to be administered after a standard care therapy. The relapse vaccine is used for the purpose of reinforcing a patient's immune system while it is healthy.

DCPrime's vaccine, the DCP-001, is a cell-based vaccine that is designed to fight against blood cancers known for relapsing in a patient. The product is in Phase II clinical trials for the purpose of treating acute myeloid leukemia. The company is primarily focused on developing therapeutic candidates for treating hematological malignancies that have a high risk of relapse, which would allow patients to avoid repeat treatments of chemotherapy or bone marrow transplants. The trials are being evaluated in patients with AML, who have responded to chemotherapy treatment, but cannot undergo bone marrow transplant procedures.

The company signed a licensing agreement with Glycotope in order to combine and advance their cancer vaccination and therapeutic antibody platforms in September of 2020.